Document Detail


Mitotic arrest and interphase inhibition induced by the pyrimidine sulfoxide NY 4138.
MedLine Citation:
PMID:  4066219     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Phase-specific cell-cycle inhibitory effects of the sulfoxide 5-bromo-2-(2-thienylmethyl)sulfinyl-pyrimidine (NY 4138) was studied on synchronized human NHIK 3025 cells cultivated in vitro. When added to exponentially growing cells, NY 4138 induced an accumulation of metaphases. The metaphase arrest was, however, not efficient immediately after addition of the compound. While a few telophases were still present 3 h after addition of 0.1 mM, no telophases were seen 6 h after addition. Most cells exposed to metaphase arrest by NY 4138 lost their ability to form colonies. We therefore characterize the metaphase arrest induced by this drug as irreversible. For concentrations above 0.5 mM phase specific cell cycle inhibition was also observed during interphase. Cells treated in G1 only were not delayed in G1 but were delayed in S and in G2. Cells treated in S only were also delayed in S, but to a smaller extent than the cells treated in G1 only. Cells treated with 0.1 mM NY 4138 for a period of 4 h in either G1 or in S showed no significant prolongation of the subsequent mitosis (i.e. the drug was in this case not present during mitosis). However, about 20% of the cells in this case divided to form 3 daughter cells of which 1 had a normal G1 DNA-content, 1 had 1/3 and 1 had 2/3 of a normal G1 DNA-content.
Authors:
E O Pettersen; O Nome; J M Dornish; R Oftebro
Related Documents :
2439359 - Elongation and shortening of time required for entry into s phase after release from g1...
15674399 - Implications of cell cycle progression on functional sequence correction by short singl...
11730009 - Transfection-mediated cell synchronization: acceleration of g1-s phase transition by ga...
1673039 - Role of la crosse virus glycoproteins in attachment of virus to host cells.
8567749 - Effect of cell cycle on the regulation of the cell surface and secreted forms of type i...
10200349 - Proliferating cell nuclear antigen as a predictor of therapeutic effect of continuous 5...
22847019 - Synthesis and one-electron reduction characteristics of radiation-activated prodrugs po...
20798479 - Progenitor radial cells and neurogenesis in pejerrey fish forebrain.
21054139 - Celecoxib and radioresistant glioblastoma-derived cd133(+) cells: improvement in radiot...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Investigational new drugs     Volume:  3     ISSN:  0167-6997     ISO Abbreviation:  Invest New Drugs     Publication Date:  1985  
Date Detail:
Created Date:  1986-01-03     Completed Date:  1986-01-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8309330     Medline TA:  Invest New Drugs     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  245-53     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cell Division / drug effects
Cells, Cultured
DNA / biosynthesis
Humans
Metaphase / drug effects
Mitosis / drug effects*
Pyrimidines / pharmacology*
Time Factors
Chemical
Reg. No./Substance:
0/Pyrimidines; 79685-11-3/NY 4138; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dezaguanine mesylate: a new antipurine antimetabolite.
Next Document:  Distribution, elimination, metabolism and bioavailability of hexamethylenebisacetamide in rats.